Inhibitory effect of high-dose Xuezhikang on inflammatory response induced by percutaneous coronary intervention in patients with unstable angina |
| |
Authors: | LIU Zun-qi CUI Lian-qun WANG Yong KONG Qing-zan LIU Ji-dong LI Feng GAI Yu-sheng ZHAO Chuan-yan |
| |
Affiliation: | Department of Cardiology,Shandong Provincial Hospital,Shandong University,Jinan 250012,China.E-mail: liubmjs@yahoo.com.cn |
| |
Abstract: | AIM: To study the inhibitory effect of high-dose Xuezhikang,administered before percutaneous coronary intervention (PCI) on inflammatory response induced by PCI in patients with unstable angina (UA).METHODS: All patients with UA in class Ⅲ and ⅡB according to Braunwald classification were considered for inclusion in the present study.Finally,196 patients received Xuezhikang treatment 72 h before coronary angiography and successfully performed PCI with elevated C-reactive protein (CRP) level (>3 mg/L) were randomised to 2 groups: 1.2 g/d of Xuezhikang as group A,or 2.4 g/d of Xuezhikang as group B.The levels of CRP were measured at baseline,after 3 days of therapy (before procedure) and 48 hours after PCI.The patients were followed-up for 6 months for major adverse coronary events and left ventricular ejection fraction.RESULTS: There was no significant difference in the mean CRP level among the two randomized groups (P>0.05),however,after three days of pharmacological treatment,there was significantly reduced CRP content in group A [(5.44±1.57) mg/L vs (4.04±1.54) mg/L,P<0.05] and in group B [(5.42±1.36) mg/L vs (3.60±1.14) mg/L,P<0.05] compared with admission.Measurements performed 48 hours after the procedure revealed a marked CRP level increase in group A (up to 9.22 mg/L±5.03 mg/L) and an obvious increase in groups B (up to 4.97 mg/L±1.75 mg/L,P<0.05) compared with pre-procedure.The serum level of CRP in B group was distinctly lower than that in A group before (P<0.05) and after the procedure (P<0.05),respectively.Major adverse coronary events during the 6-month clinical follow-up occurred less in group A than that in group B [21/104 (20.2%) vs 9/92 (9.8%); patients,P<0.05].Follow-up echocardiography revealed lower left ventricular ejection fraction in group A than that in group B (55.41%±10.93% vs 59.30%±9.99%,P<0.05).CONCLUSION: High-dose Xuezhikang therapy,administered before PCI,has better inhibition effect than low-dose on inflammatory response induced by PCI in patients with UA.Attenuation of inflammatory response may be crucial for the reduction of coronary events following invasive coronary interventions. |
| |
Keywords: | Xuezhikang Drugs Chinese herbal Percutaneous coronary intervention Angina unstable C-reactive protein |
|
| 点击此处可从《园艺学报》浏览原始摘要信息 |
|
点击此处可从《园艺学报》下载全文 |
|